Cannabidiol CBD

An analytical reference standard categorized as a phytocannabinoid considered an impurity in commercial preparations of cannabidiol intended for research and forensic applications

An analytical reference standard categorized as a phytocannabinoid a bis-homolog of cannabidiol intended for research and forensic applications

An analytical reference standard categorized as a phytocannabinoid a bis-homolog of cannabidiol intended for research and forensic applications

An analytical reference standard that is structurally similar to known phytocannabinoids intended for research and forensic applications

An analytical reference standard that is structurally similar to known phytocannabinoids intended for research and forensic applications

Biochem/physiol Actions Cbz-B3A is a potent and selective inhibitor of mTORC1 signaling that inhibits the phosphorylation of eIF4E binding protein 1 (4EBP1) and blocks 68% of translation. Cbz-B3A binds to ubiquilins 1, 2, and 4, which prevents

Cannabinoid compounds include exogenous drugs such as D9-THC, the main psychoactive component of the plant Cannabis sativa, and endogenous mediators, such as anandamide, that belong to eicosanoid family.The biological effects of cannabinoids are

The Cannabinoid receptor 2 (CNR2) is a G_i/o-coupled GPCR expressed in spleen, tonsils, bone marrow and peripheral blood leukocytes. There is one report that cannabinoid-induced inhibition of helper T cell activation is lost in macrophages

Application(Z)-2-Nonen-1-ol is an intermediate in the synthesis of Falcarinol, a covalent cannabinoid CB1 receptor antagonist and induces pro-allergic effects in skin.

Application(Z)-2-Nonen-1-ol is an intermediate in the synthesis of Falcarinol, a covalent cannabinoid CB1 receptor antagonist and induces pro-allergic effects in skin.

Application(Z)-2-Nonen-1-ol is an intermediate in the synthesis of Falcarinol, a covalent cannabinoid CB1 receptor antagonist and induces pro-allergic effects in skin.

CP-55940 is a cannabimimetic small molecule and a potent cannabinoid receptor agonist, demonstrating similar binding activity at both receptor types (CB1 K|i|=0.58 nM, CB2 K|i|=0.69 nM). CP-55940 represents a useful non-selective agonist entry into